Zhongren Wu
Overview
Explore the profile of Zhongren Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Q, Wu Z, Zhang J, Firrman J, Wei H, Zhuang Z, et al.
Mol Ther Methods Clin Dev
. 2017 Dec;
7:146-156.
PMID: 29255740
Recombinant adeno-associated viral (rAAV) vectors have been widely used in human gene therapy. One major impediment to its broad application is the inability to produce high-quality vectors in mass quantity....
2.
Wang Q, Dong B, Pokiniewski K, Firrman J, Wu Z, Chin M, et al.
Mol Ther Methods Clin Dev
. 2017 Mar;
4:149-158.
PMID: 28345000
Adeno-associated virus (AAV) vectors have emerged as a safe and efficient gene therapy platform. One complication is that a significant amount of empty particles have always been generated as impurities...
3.
Tice C, Noto P, Fan K, Zhao W, Lotesta S, Dong C, et al.
Bioorg Med Chem Lett
. 2016 Sep;
26(20):5044-5050.
PMID: 27599745
Liver X receptor (LXR) agonists have been reported to lower brain amyloid beta (Aβ) and thus to have potential for the treatment of Alzheimer's disease. Structure and property based design...
4.
Wang Q, Firrman J, Wu Z, Pokiniewski K, Valencia C, Wang H, et al.
Hum Gene Ther
. 2016 Aug;
27(12):971-981.
PMID: 27550145
Recombinant adeno-associated viral (rAAV) vectors have recently achieved clinical successes in human gene therapy. However, the commonly observed, heavier particles found in rAAV preparations have traditionally been ignored due to...
5.
Zheng Y, Zhuang L, Fan K, Tice C, Zhao W, Dong C, et al.
J Med Chem
. 2016 Mar;
59(7):3264-71.
PMID: 26990539
This article describes the application of Contour to the design and discovery of a novel, potent, orally efficacious liver X receptor β (LXRβ) agonist (17). Contour technology is a structure-based...
6.
Jia L, Simpson R, Yuan J, Xu Z, Zhao W, Cacatian S, et al.
ACS Med Chem Lett
. 2014 Jun;
2(10):747-51.
PMID: 24900262
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with...
7.
Yuan J, Simpson R, Zhao W, Tice C, Xu Z, Cacatian S, et al.
Bioorg Med Chem Lett
. 2011 Jul;
21(16):4836-43.
PMID: 21741239
Structure-based design led to the discovery of a novel class of renin inhibitors in which an unprecedented phenyl ring filling the S1 site is attached to the phenyl ring filling...
8.
Xu Z, Cacatian S, Yuan J, Simpson R, Jia L, Zhao W, et al.
Bioorg Med Chem Lett
. 2009 Dec;
20(2):694-9.
PMID: 19959358
Structure-guided drug design led to new alkylamine renin inhibitors with improved in vitro and in vivo potency. Lead compound 21a, has an IC(50) of 0.83nM for the inhibition of human...
9.
Tice C, Xu Z, Yuan J, Simpson R, Cacatian S, Flaherty P, et al.
Bioorg Med Chem Lett
. 2009 May;
19(13):3541-5.
PMID: 19457666
Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC(50)...
10.
Wu Z, Cappiello M, Scott B, Bukhtiyarov Y, McGeehan G
BMC Biochem
. 2008 Jun;
9:19.
PMID: 18582379
Background: The renin-angiotensin-aldosterone system (RAS) cascade is a major target for the clinical management of hypertension. Although inhibitors of various components of this cascade have been developed successfully, development of...